Report Company Directory

AEQUUS PHARMACEUTICALS

• Aequus Reports Second Quarter 2023 Financial Highlights and General Update by GlobeNewsWire
• Aequus Announces Zimed PF Now Available in Canada by GlobeNewsWire
• Aequus Announces Zimed PF Website Launch by GlobeNewsWire
• Aequus Pharmaceutical Canada Announces a Pause in Sales of Evolve Intensive Eyedrops and Gel in Canada by GlobeNewsWire
• Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%) by GlobeNewsWire
• Aequus Provides General Update and First Quarter 2023 Financial Highlights by GlobeNewsWire
• Aequus Provides General Update and Fiscal 2022 Financial Results by GlobeNewsWire
• Aequus Grants Stock Options by GlobeNewsWire
• Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%) and Board Update by GlobeNewsWire
• Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%) by GlobeNewsWire

AER ENERGY RESOURCES INC

AerCap Holdings NV

• Aercap Holdings NV: 1 director by SmartInsider
• Vital Signs: Actionable charts by Vermilion Research
• U.S. Consumer Finance: Weekly Debrief | Issue 53 by Barclays
• U.S. Consumer Finance: Weekly Debrief | Issue 52 by Barclays
• U.S. Consumer Finance: Weekly Debrief | Issue 51 by Barclays
• U.S. Consumer Finance: Weekly Debrief | Issue 50 by Barclays
• U.S. Consumer Finance: Weekly Debrief | Issue 49 by Barclays
• U.S. Consumer Finance: Weekly Debrief | Issue 48 by Barclays
• AerCap Holdings: 3Q24 Earnings Review: Strong Fundamentals Continue by Barclays
• AerCap Holdings: 3Q24 First Look - Another Solid Quarter by Barclays

Aeria Inc.

• Ford Equity International Rating and Forecast Report by Ford Equity Research

Aerie Pharmaceuticals Inc.

• Raymond James Afternoon Notes by Raymond James
• AERI | Dropping Coverage Following Completed Acquisition by Alcon by Raymond James
• AERI | Weekly Rx Metrics: Rocklatan Tops New High, Glaucoma Franchise Tracks in Line With Estimates by Raymond James
• AERI | Weekly Rx Metrics: New Rhopressa High Follows Late-August Acquisition Announcement by Raymond James
• AERI | I Love Rock 'N Rho; Alcon Bid Relieves Burn & Valuation Pressure While Keeping Pipeline Alive by Raymond James
• AERI | 2Q22 Update: How Low Can You Flow? AERI Eyes Cash Break Even as Key Dry Eye Trial Kicks Off by Raymond James
• AERI | Weekly Rx Metrics: Weekly AERI Franchise RXs Driven By Overall Glacuoma Market Downtick by Raymond James
• AERI | Weekly Rx Metrics: New Glaucoma Share High but Franchise Still Tracking to Low End of Guide by Raymond James
• AERI | Weekly Rx Metrics: New Rocklatan High Moves Sales Projection and Glaucoma Market Share Upward by Raymond James
• Vermilion Compass: Weekly Equity Strategy by Vermilion Research